Flexion Therapeutics Inc. (NASDAQ: FLXN) shares popped on Friday after the company announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) to update the product label for Zilretta for the treatment of osteoarthritis (OA) knee pain.
One of the key elements of the label update is the removal of language that stated Zilretta was “not intended for repeat administration.” The updated label states that the “efficacy and safety of repeat administration of Zilretta have not been demonstrated.”
The label update will include a study description and safety data from the single-arm, open-label Phase 3 repeat administration trial. It also will remove a misleading statement describing a single secondary exploratory endpoint in the original Phase 3 pivotal trial that compared Zilretta to immediate-release triamcinolone acetonide crystalline suspension.
Michael Clayman, M.D., president and CEO of Flexion, commented:
We are very pleased with the new product label as it achieves our primary goal of removing unclear language pertaining to repeat administration, which we believe was potentially confusing to patients, physicians and payers alike. In addition, we are gratified by the inclusion of safety data from our repeat administration trial and the removal of the inappropriate comparator statement. We believe the updated label supports our goal of seeing Zilretta become the leading intra-articular therapy for managing OA knee pain.
In 2016, Zilretta was approved by the FDA as the first and only extended-release intra-articular therapy for patients confronting OA-related knee pain. The pivotal Phase 3 trial on which the approval of Zilretta was based demonstrated that Zilretta significantly reduced knee pain for 12 weeks, with some people experiencing pain relief through week 16.
Shares of Flexion closed Thursday at $19.17, in a 52-week range of $8.76 to $21.39. The consensus price target is $27.10. Following the announcement, the stock was up about 19% at $22.77 in early trading indications Friday.
ALERT: Today Could Be Your Best Shot At Early Retirement (Sponsored)
If you want to retire before 65, pay attention. Study after study has shown that the longer you stay invested, the better your chances at an early retirement.
Every day that goes by without saving and investing for tomorrow means more to earn and save later. Don’t waste any more time and get started with Robinhood today. The app makes it easy to buy and sell stocks, mutual funds, trade options, and even cryptocurrencies.
Sign up today — click here to start your journey.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.